USFDA completes inspection at Lupin’s injectable facility in Nagpur

14 Jun 2024 Evaluate

United States Food and Drug Administration (USFDA) has completed an inspection at Lupin’s Injectable facility in Nagpur, India. The inspection of the facility was carried out from June 10 to June 13, 2024, and concluded with zero 483 observations. 

Earlier, the company had entered into Business Transfer Agreement (BTA) with Lupin Life Sciences (LLSL) wholly owned subsidiary of the Company, to carve out, its trade generics business in India, as a going concern, on a slump sale basis.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2147.55 -14.65 (-0.68%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.